Integra LifeSciences Holdings Corporation (IART) Cash Flow Statement

The OCF/NI ratio of 5.09 in Q2 2026 appears flattered by a large working capital inflow, which may reverse in subsequent quarters. Excluding working capital changes, cash generation from core operations remains thin, consistent with prior quarters where OCF often lagged net income. Investors should monitor whether working capital swings continue to mask underlying operational cash conversion.

The erratic FCF pattern aligns with the company's ongoing manufacturing remediation and product re-launch efforts, which appear to disrupt both revenue and capital spending. While Q2 2026 showed a positive FCF margin of 9.0%, this is an outlier relative to the prior five quarters, suggesting that sustainable FCF generation has yet to be established. The negative net income in most quarters further underscores that FCF is not yet driven by underlying profitability.

The spike in capital intensity during 2025 likely reflects investments in quality remediation and capacity upgrades, which may be necessary to resolve regulatory issues but are not yet translating into revenue growth. The recent moderation in CapEx/Rev to 3.5% could indicate a pause in spending, but given the company's history of manufacturing lapses, investors should watch whether this is a temporary reprieve or a sign of underinvestment.

The large positive working capital adjustment in Q2 2026 appears to be a key driver of the quarter's cash flow beat, but such swings are inherently volatile and may reverse. The negative working capital changes in several prior quarters suggest that the company has been managing payables and receivables inconsistently, possibly due to supply chain disruptions. This volatility complicates the assessment of underlying cash generation and warrants close monitoring of days sales outstanding and inventory levels.

The absence of dividends and buybacks suggests that management is prioritizing balance sheet repair and operational turnaround over returning capital to shareholders. The $282M acquisition outflow in Q2 2024, likely related to portfolio optimization, appears to have been a one-time event, but it underscores the company's acquisitive history. Given the negative net income and ongoing remediation costs, capital deployment is likely to remain conservative in the near term.

The gap between cumulative net income and operating cash flow suggests that non-cash charges, such as impairments and depreciation, are inflating losses without corresponding cash outflows. However, the positive cumulative OCF is largely driven by working capital inflows and non-cash add-backs, which may not be sustainable. This divergence implies that the company's cash flow is more resilient than its earnings suggest, but the underlying operational profitability remains weak.